Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

@article{Treon2009LongtermOT,
  title={Long-term outcomes to fludarabine and rituximab in Waldenstr{\"o}m macroglobulinemia.},
  author={Steven P Treon and Andrew Branagan and Leukothea Ioakimidis and Jacob D Soumerai and Christopher J. Patterson and Barry Turnbull and Parveen Wasi and Christos Emmanouilides and Stanley R. Frankel and Andrew Lister and Pierre Morel and Jeffrey V. Matous and Stephanie A. Gregory and Eva K Kimby},
  journal={Blood},
  year={2009},
  volume={113 16},
  pages={3673-8}
}
We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m(2) per day for 5 days) of fludarabine and 8 infusions (375 mg/m(2) per week) of rituximab. A total of 43… CONTINUE READING